Posts by: Kara Elam

News

Reldesemtiv improved muscle strength for walking and respiration in a dose-dependent manner in spinal muscular atrophy (SMA) patients, data from a Phase 2 clinical trial show. As a fast muscle ... Read more

December 1, 2015December 1, 2015

Impaired Mitochondrial Dynamics Play Role in SMA Pathology

News, Spinal Muscular Atrophy

The degeneration of spinal motor neurons in spinal muscular atrophy (SMA) may be the direct result of abnormal mitochondrial (energy source of cells) transport and morphology and subsequent reduced mitochondrial health. ... Read more

November 17, 2015November 17, 2015

Spinal Muscular Atrophy Study Points to Blood Vessel Defects

News

U.K. researchers funded by the SMA Trust have found that insufficient blood supply may well contribute to motor neuron loss in spinal muscular atrophy (SMA). The study entitled, “Vascular defects and spinal ... Read more

March 3, 2015November 30, 2016

SMA Drug Developer AveXis Forms AveXis EU as European Subsidiary

News, Spinal Muscular Atrophy

Dallas, Texas-based AveXis, Inc., a biotechnology company currently developing an experimental therapy for Spinal Muscular Atrophy (SMA) through the use of innovative gene therapy, recently announced that they have established a European Union (EU) ... Read more

January 21, 2015January 21, 2015

Challenging the Assumptions for Effective SMA Drug Administration

News, Spinal Muscular Atrophy

A study published by a team of researchers at the Cold Spring Harbor Laboratory (CSHL) suggests that a drug to treat spinal muscular atrophy (SMA) in a mouse model ... Read more

Posts by: Kara Elam

Kara Elam

#CureSMA2018 – Reldesemtiv Improves Muscle Strength in SMA Patients, Trial Data Show

Impaired Mitochondrial Dynamics Play Role in SMA Pathology

Spinal Muscular Atrophy Study Points to Blood Vessel Defects

SMA Drug Developer AveXis Forms AveXis EU as European Subsidiary

Challenging the Assumptions for Effective SMA Drug Administration

Pin It on Pinterest